Agenus Inc. (NASDAQ:AGEN) Given Buy Rating at Jefferies Group LLC
Agenus Inc. (NASDAQ:AGEN)‘s stock had its “buy” rating reissued by equities researchers at Jefferies Group LLC in a report issued on Friday. They currently have a $7.00 target price on the biotechnology company’s stock. Jefferies Group LLC’s price target points to a potential upside of 74.13% from the stock’s previous close.
Other analysts have also recently issued research reports about the stock. HC Wainwright set a $5.00 price objective on shares of Agenus and gave the company a “hold” rating in a research note on Saturday, May 6th. BidaskClub lowered shares of Agenus from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine lowered shares of Agenus from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Wednesday, July 5th. Finally, Maxim Group reiterated a “buy” rating and issued a $7.00 target price on shares of Agenus in a report on Sunday, April 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $5.88.
Shares of Agenus (NASDAQ AGEN) traded down 4.74% during mid-day trading on Friday, reaching $4.02. 1,247,487 shares of the company’s stock traded hands. The company’s 50-day moving average price is $4.26 and its 200-day moving average price is $3.90. The stock’s market capitalization is $398.45 million. Agenus has a 12-month low of $3.20 and a 12-month high of $7.49.
Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. Agenus had a negative net margin of 280.96% and a negative return on equity of 37,577.49%. The company had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $6.66 million. During the same quarter in the prior year, the company earned ($0.33) EPS. Agenus’s revenue was down 36.1% compared to the same quarter last year. Analysts anticipate that Agenus will post ($1.17) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Agenus Inc. (NASDAQ:AGEN) Given Buy Rating at Jefferies Group LLC” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/05/agenus-inc-nasdaqagen-given-buy-rating-at-jefferies-group-llc.html.
A number of institutional investors have recently bought and sold shares of AGEN. State Street Corp raised its position in Agenus by 64.3% in the fourth quarter. State Street Corp now owns 3,502,274 shares of the biotechnology company’s stock valued at $14,430,000 after buying an additional 1,370,515 shares during the last quarter. Vanguard Group Inc. raised its position in Agenus by 6.8% in the first quarter. Vanguard Group Inc. now owns 3,356,423 shares of the biotechnology company’s stock valued at $12,653,000 after buying an additional 215,151 shares during the last quarter. Oracle Investment Management Inc. purchased a new position in Agenus during the first quarter valued at $6,444,000. Goldman Sachs Group Inc. raised its position in Agenus by 3,447.2% in the first quarter. Goldman Sachs Group Inc. now owns 673,333 shares of the biotechnology company’s stock valued at $2,539,000 after buying an additional 654,351 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Agenus by 38.1% in the first quarter. Bank of New York Mellon Corp now owns 560,799 shares of the biotechnology company’s stock valued at $2,114,000 after buying an additional 154,715 shares during the last quarter. Institutional investors own 42.58% of the company’s stock.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.